Individuals may not develop mesothelioma symptoms for decades after being exposed and there is currently no cure for this form of cancer.
Austin, Texas (PRWEB) November 13, 2013
A study by the National Cancer Institute reports that a promising treatment could benefit some patients with mesothelioma, according to Hissey Kientz, LLP. Science Translational Medicine journal published the study findings in their October 2013 article, “Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression.”
The study tested a mesothelioma treatment involving the immunotoxin SS1P that targets the protein mesothelin present on mesothelioma cells. Out of the 10 patients treated in the study, three experienced significant tumor shrinkage after receiving doses of SS1P and are alive more than 18 months after starting therapy. Two patients also had a tumor response after being treated with chemotherapy following the SS1P dose.*
Mesothelioma cancer is generally linked to asbestos exposure. Asbestos is a naturally-occurring mineral used in many industrial, construction and manufacturing products during the 1940s to the 1970s. Individuals may not develop mesothelioma symptoms for decades after being exposed and there is currently no cure for this form of cancer. The symptoms of the disease can include breathing problems, chest pain, abdominal pain, nausea or weakness.**
Hissey Kientz, LLP is currently accepting cases involving individuals who may have contracted mesothelioma or lung cancer as a result of asbestos exposure. For a free legal consultation, contact the lawyers at Hissey Kientz, LLP by calling toll-free at 1-866-275-4454, or by email at info(at)hkllp(dot)com.
About Hissey Kientz, LLP
Hissey Kientz, LLP represents victims of mesothelioma and other asbestos-related diseases, individuals experiencing complications from Zoloft use during pregnancy, as well as Mirena IUDs, Stryker and BioMet hip replacements, transvaginal mesh implants, GranuFlo dialysis concentrate and other defective drugs and medical devices.